Slide 1: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery August 2026
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schröding
Slide 3: Recent Updates
Recent Updates 2Q26 Financials & Hosted Platform & Portfolio Transition • $29.6M ACV (+27%) • Launched early access version of Bunsen in July – $22.6M ACV excluding contribution (+23%) • Announced strategic collaboration and software agreement with BMS to deploy Bunsen within • $23.0M drug discovery
Slide 4: Multi-Pronged Business Enabled by Highly Differentiated Computational Platform
Multi-Pronged Business Enabled by Highly Differentiated Computational Platform SOFTWARE LICENSING THERAPEUTICS PORTFOLIO • Accelerating molecular design for Life • Full-scale application of predict-first Sciences and Materials Science global approach producing highly differentiated customers molecul
Slide 5: Schrödinger's Vision for the Future of Molecular Discovery
Schrödinger’s Vision for the Future of Molecular Discovery If all properties can be calculated with perfect accuracy, designing drugs/materials would have a much higher success rate, be much faster and cheaper, and would produce much higher-quality molecules. Select THE best molecule Physics-powered
Slide 6: Schrödinger's Platform Uniquely Addresses the Challenge of Data Scarcity in Molecular Discovery
Schrödinger’s Platform Uniquely Addresses the Challenge of Data Scarcity in Molecular Discovery Highly sophisticated Simulated data is needed AI applications rely on to unlock power of AI simulated data Autonomous Vehicles Weather Prediction AI models in molecular discovery require Chip Design Physi
Slide 7: Bunsen Early Access Version Launched
Bunsen Early Access Version Launched What It Is Optimized to the Agentic AI Co-Scientist that helps Entire Platform understand, plan, execute, and Executes Schrödinger’s validated interpret complex computational computational methods in small molecule Analyze the protein-protein interface between my
Slide 8: 2Q26 Financial Highlights vs. 2Q25
2Q26 Financial Highlights vs. 2Q25 Three Months Ended June 30 2Q 2026 2Q 2025 % Change ($M) ($M) Software revenue $32.5 $36.0 (10%) Drug discovery revenue $23.0 $13.9 65% Contribution revenue $3.4 $4.8 (30%)* Total revenue $58.9 $54.8 7.5% Gross profit $32.4 $26.2 Software gross margin 71% 76% Opera
Slide 9: 2026 Financial Outlook and 2028 Financial Objectives
2026 Financial Outlook and 2028 Financial Objectives 2026 Financial and Operational Outlook 2028 Financial Objectives • ACV of $218 – $228M, representing 10-15% • Durable ACV growth of 10-15% annually growth over 2025 • Substantially complete transition to hosted • Drug discovery revenue of $65 – $7
Slide 10: Therapeutics Strategy: Over $750M Cash Realized to Date
Therapeutics Strategy: Over $750M Cash Realized to Date Equity Stakes Drug Discovery Revenue Multiple M&A events → cash • Proprietary programs licensed to pharma Current equity stakes in: • $56M revenue in 2025 • Nimbus Therapeutics • 21 collaborators since 2018 • Structure Therapeutics Milestones &
Slide 11: Extensive History of Monetization Events Spanning Co-invented Drugs & Schrödinger Co-Founded Companies
Extensive History of Monetization Events Spanning Co-invented Drugs & Schrödinger Co-Founded Companies Gilead Acquires Lilly Acquires Relay Therapeutics Takeda Acquires Nimbus ACC Inhibitor Petra Pharma Successful IPO Nimbus TYK2 Inhibitor $1.2B Undisclosed $400M Raised $6.0B April 2016* May 2020 Ju
Slide 12: Significant Upside Potential from Collaboration Programs
Significant Upside Potential from Collaboration Programs Therapeutic Area Potential Partner Target Phase Milestones Royalties6 1 Inflammation (Psoriasis) TYK25 Phase 3 Up to $100M7 - 1 IBD (UC/Crohn’s) α4β73 Phase 2 Undisclosed LSDs Cardiometabolic GLP-18 Phase 2 - - 1 Oncology (Myelofibrosis) JAK22
Slide 13: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery August 2026
Slide 14: Appendix
APPENDIX @ Schrédinger
Slide 15: Definitions
Definitions Annual Contract Value (ACV). Schrödinger tracks the ACV for each customer. With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, ACV is defined as the contract value billed during the applicable period
Slide 16: Definitions
Definitions Ongoing programs eligible for royalties. Schrödinger tracks the aggregate number of collaborative and partnered programs for which the company is eligible to receive any amount of future royalties on sales, if any. Numbers of collaborators since 2018. Schrödinger tracks the aggregate num
Slide 17: Non-GAAP Information
Non-GAAP Information Included in this presentation is certain financial information that has not been prepared in accordance with generally accepted accounting principles in the Three Months Ended June 30 United States (GAAP). The company presents adjusted EBITDA, which is a non-GAAP financial measu
Slide 18: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery August 2026